Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elevation Oncology ( (ELEV) ) has issued an update.
Elevation Oncology, Inc. announced the completion of a merger with Concentra Biosciences, LLC on July 23, 2025. The merger involved Concentra’s subsidiary, Merger Sub VI, Inc., acquiring all outstanding shares of Elevation Oncology through a tender offer. As a result, Elevation Oncology became a wholly owned subsidiary of Concentra. The merger led to the delisting of Elevation Oncology’s shares from Nasdaq and the termination of its registration under the Securities Exchange Act of 1934.
The most recent analyst rating on (ELEV) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Elevation Oncology stock, see the ELEV Stock Forecast page.
Spark’s Take on ELEV Stock
According to Spark, TipRanks’ AI Analyst, ELEV is a Underperform.
Elevation Oncology’s overall stock score is low due to its lack of revenue, ongoing losses, and reliance on external financing, typical of an early-stage biotech firm. Recent corporate restructuring and product discontinuation further dampen the outlook, despite a stable cash position. The technical analysis shows a downward trend, adding to the challenges in valuation. Investors should be cautious and consider the speculative nature of this stock.
To see Spark’s full report on ELEV stock, click here.
More about Elevation Oncology
Average Trading Volume: 1,353,016
Technical Sentiment Signal: Sell
Current Market Cap: $21.62M
For an in-depth examination of ELEV stock, go to TipRanks’ Overview page.